Sharp Edge Labs

Sharp Edge Labs is a preclinical-stage life sciences company located in Pittsburgh, Pennsylvania. The company employs 10 people and generates annual revenue of $1 million. Sharp Edge Labs is focused on developing orally-available small molecule drugs to treat genetic diseases. Their platform targets monogenic diseases, which allows for a more defined clinical pathway. Each program in their pipeline has a genetically identifiable patient population and an early Phase IB pharmacodynamic readout. The company's three core technologies, CoreX(tm), AlloChem(tm), and Disco/Mine(tm), create a scalable platform for drug discovery and development. CoreX(tm) utilizes assay technologies to create realistic cellular models of genetic diseases. AlloChem(tm) is a proprietary compound library that is computationally designed to contain molecules capable of allosterically binding proteins, stabilizing them and restoring their function. Disco/Mine(tm) is a suite of computational and machine learning tools that complements their experimental approach. For more information, please visit sharptx.com.